Novavax’s COVID-19 vaccine headed into the clinic; data due in July
BioCentury is providing this story for free given the urgent need for information about the COVID-19 crisis. For more analysis, sign up for our daily email.
Novavax could have preliminary data as soon as July from a planned first-in-human trial of its COVID-19 vaccine, the company said Wednesday.
Next month, Novavax Inc. (NASDAQ:NVAX) intends to start the Phase I trial of NVX-CoV2373, with about 130 healthy adult subjects receiving the vaccine or placebo. Novavax said the trial is starting weeks ahead of schedule; early safety and immunogenicity results are due two months later.
Novavax’s entrant would follow a handful of other vaccines into the clinic. NIH began a Phase I study last month of MRNA-1273, the vaccine candidate developed by Moderna Inc. (NASDAQ:MRNA), while Chinese regulators last month cleared CanSino Biologics Inc. (HKSE:6185) to begin a Phase I study of its vaccine, Ad5-nCoV. And on Monday, Inovio Pharmaceuticals Inc. (NASDAQ:INO) said it had begun a Phase I study of INO-4800.
Novavax would follow the Phase I trial with a Phase II study. NVX-CoV2373 uses the company’s recombinant nanoparticle technology and Matrix-M adjuvant.
The Coalition for Epidemic Preparedness Innovations has funded Novavax with $4 million for its COVID-19 vaccine development. The company said Wednesday it is discussing additional funding with CEPI.
Novavax climbed $2.28 (15%) to $17.18 Wednesday.
Further analysis of the coronavirus crisis can be found at https://www.biocentury.com/coronavirus.